Category: Novartis

  • The exec who decides which drugs Novartis will develop

    At the beginning of 2023, Dr. Roni (Aharon) Gal, one of the best-known and longest-serving analysts in biopharmaceuticals, surprised the market when he announced his career change. Gall, who was working as a senior analyst at investment bank Sanford Bernstein, crossed the lines and joined pharmaceutical company Novartis as chief…